Sildenafil citrate for erectile dysfunction in male kidney transplant recipients.
- Author:
Feng LIU
1
;
Genfu ZHANG
;
Xining JI
;
Chibing HUANG
;
Pingxian WANG
;
Mingqi FAN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Erectile Dysfunction; drug therapy; Humans; Kidney Transplantation; Male; Middle Aged; Piperazines; adverse effects; therapeutic use; Purines; Sildenafil Citrate; Sulfones
- From: National Journal of Andrology 2004;10(6):455-457
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of sildenafil citrate in man kidney transplant recipients with erectile dysfunction.
METHODSOne hundred and seventy married males, aged 26 approximately 50 years, who had received kidney transplantations at least half a year before and whose serum creatinine was under 133 umol/l, were selected randomly in the study. Their sexual function was investigated according to the International Index of Erectile Function-5 (IIEF-5), and those with erectile dysfunction (ED) were treated with oral sildenafil citrate for 6 months. The efficacy was assessed by IIEF-5.
RESULTSFifty-three men with ED received oral sildenafil citrate for 6 months. At the end of the treatment, each index in IIEF-5 increased significantly. There were no interactions between sildenafil and cyclosporine and there was no significant adverse effect of sildenafil on the graft function.
CONCLUSIONSildenafil is an effective and safe agent for the treatment of ED in kidney transplant recipients.
